Recurrent Melanoma Completed Phase 2 Trials for Vorinostat (DB02546)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00121225Vorinostat in Treating Patients With Metastatic or Unresectable MelanomaTreatment